Internal Mammary Lymph Nodes Irradiation in High-risk Breast Cancer After Neoadjuvant Chemotherapy

Abroad (travel likely)RecruitingPHASE3

Conditions

Breast Cancer

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Fujian Medical University Union Hospital, Fuzhou, Fujian, China
Contact: Study coordinator (Yong Yang, Doctor) · dr_yangyong1983@163.com · 18813019084

Study leads

Yong Yang, M.S
Principal Investigator
Fujian Medical University Union Hospital

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease

HR+/HER2- Breast Cancer

Abroad (travel likely)RecruitingPHASE3

Birmingham, United States · Anchorage, United States

A Trial Comparing GQ1005 and T-DM1 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer

HER2-positive Breast Cancer

Abroad (travel likely)RecruitingPHASE3

Bengbu, China · Fuyang, China

Chemotherapy De-escalation in HR +, HER2-, Intermediate-risk Early Breast Cancer Treated With Adjuvant Ribociclib

Breast Cancer

Abroad (travel likely)RecruitingPHASE3

Amiens, France · Angers, France

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

High Grade Epithelial Ovarian Cancer · High Grade Serous Ovarian Cancer · Primary Peritoneal Carcinoma

Abroad (travel likely)RecruitingPHASE1, PHASE2

Phoenix, United States · Tucson, United States